قالب وردپرس درنا توس
Home / WorldTech / Opioid Maker Purdue promises not to benefit from its new overdose

Opioid Maker Purdue promises not to benefit from its new overdose



Image: Andrew Burton (Getty Images)

One of the main instigators of the opioid crisis is to sell its own drug to save people from deadly overdoses – but the company swears that it will not pin its profits ,

This week, pharmaceutical company Purdue Pharma announced that its antidote to opioid overdoses has been labeled a "fast track" by the Food and Drug Administration. The status is intended to accelerate the review process for new drugs in serious diseases that would otherwise not be covered by existing treatments. In this case, Purdue claims that his drug, derived from the opioid antagonist nalmefene, could be a more potent, longer-lasting version of naloxone, the only currently approved drug to reverse the effects of an opioid overdose in an emergency situation. [19659003PurduesaggressiveVermarktungseinesgeschätztenOpioid-SchmerzmittelsOxycontinspielteinden1990erund2000erJahreneineentscheidendeRollebeiderSteigerungderRatenvonOpioid-KonsumstörungenbeiAmerikanernSelbstnachdemdasUnternehmenundseineFührungskräftesichschuldigfürdieIrreführungderÖffentlichkeitüberdieRisikenderDrogeimJahr2007geäußerthattenhabendieGerichtsverfahrenindenBundesstaatenundderGrafschaftPurduevorgeworfenweiterhinvonirreführendemOpioid-MarketingprofitiertzuhabenwährendsiedenÄrztendiedieSchwarzenüberfluteteneinAugezudrückenMarktmitihrenMedikamentenoderdenPatientenmitgefährlichenDosenverschrieben

From one of these lawsuits filed by the Massachusetts Attorney General, we know that this is not the first time that Purdue has the idea of ​​an overdose treatment in addition to his sell painkillers

According the documents collected by the Prosecution, sealed by the court since the dish was unsealed, were discussed d The Purdue executives expressed their hopes of entering the lucrative and "attractive" market of addiction treatment in 2014 – and even set up a code-name, Project Tango. At that time, they had bought the rights to sell Narcan, the brand name brand. Spray version of Naloxone, and Suboxone, a version of the opioid craving and withdrawal drug buprenorphine, which was administered through a film under the tongue. In a statement to Propublica and Stat News in January, Purdue said he had finally decided against one of the two steps. Instead, it seems that it has decided to compete with Narcan.

Hoping to stem some of the predicted backlash, the financially struggling company promised in its announcement "to advance this option with pledge" Benefit from future sales of this medicine. Last fall, it also committed $ 3.4 million to the non-profit Harm Reduction Therapeutics to help develop a generic version of a Naloxone spray.

The experimental drug of Purdue would not necessarily do much of a cash cow. His version of Nalmefen, an injection of nalmefene hydrochloride (HCI), was approved by the FDA in 1995 as an opioid reversal drug under the Revex brand name. In 2009, however, the drug maker decided to discontinue Revex's production, claiming it was solely for business reasons. A subsequent FDA review released in 2017 revealed that Revex was not put on ice because it did not work or had any dangerous side effects. (In fact, nalmefene is currently approved for the treatment of alcohol dependence in the EU).

The decision, the agency added, also paved the way for approval of Nalmefene HCI with little effort. And at least one other pharmaceutical company is pursuing its own nasal spray version of nalmefene with the blessing of the federal government.


Source link